Dott. Giovanni Salamano Studio Medico

16/06/2026

04/06/2026

Research Summaries accompanying Original Articles in the May 28, 2026, issue of NEJM:

𝐂𝐚𝐭𝐡𝐞𝐭𝐞𝐫-𝐃𝐢𝐫𝐞𝐜𝐭𝐞𝐝 𝐅𝐢𝐛𝐫𝐢𝐧𝐨𝐥𝐲𝐬𝐢𝐬 𝐟𝐨𝐫 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐄𝐦𝐛𝐨𝐥𝐢𝐬𝐦 (𝐇𝐈-𝐏𝐄𝐈𝐓𝐇𝐎)
In patients with pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis led to a lower risk of a composite of major adverse outcomes than anticoagulation alone.

𝐙𝐚𝐧𝐢𝐝𝐚𝐭𝐚𝐦𝐚𝐛 𝐢𝐧 𝐇𝐄𝐑𝟐-𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐆𝐚𝐬𝐭𝐫𝐨𝐞𝐬𝐨𝐩𝐡𝐚𝐠𝐞𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 (𝐇𝐄𝐑𝐈𝐙𝐎𝐍-𝐆𝐄𝐀-𝟎𝟏)
In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy.

𝐃𝐞𝐜𝐨𝐦𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐨𝐫 𝐰𝐢𝐭𝐡𝐨𝐮𝐭 𝐃𝐮𝐫𝐚𝐩𝐥𝐚𝐬𝐭𝐲 𝐟𝐨𝐫 𝐂𝐡𝐢𝐚𝐫𝐢 𝐈 𝐚𝐧𝐝 𝐒𝐲𝐫𝐢𝐧𝐠𝐨𝐦𝐲𝐞𝐥𝐢𝐚
In a trial involving children with Chiari type I malformation and syringomyelia, the percentage with surgical complications did not differ significantly between posterior fossa decompression with duraplasty and decompression alone.

Read the full articles and Research Summaries at NEJM.org (link in bio).

04/06/2026

Research Summaries accompanying Original Articles in the May 14/21, 2026, issue of NEJM:

𝐀 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐓𝐫𝐢𝐚𝐥 𝐨𝐟 𝐁𝐫𝐞𝐩𝐨𝐜𝐢𝐭𝐢𝐧𝐢𝐛 𝐢𝐧 𝐃𝐞𝐫𝐦𝐚𝐭𝐨𝐦𝐲𝐨𝐬𝐢𝐭𝐢𝐬 (𝐕𝐀𝐋𝐎𝐑)
In the phase 3 VALOR trial of brepocitinib in adults with dermatomyositis, the 30-mg dose (but not the 15-mg dose) led to greater improvement on a composite myositis index at 52 weeks than placebo. Serious infections were more frequent with the 30-mg dose.

𝐄𝐧𝐝𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐌𝐞𝐝𝐢𝐮𝐦-𝐕𝐞𝐬𝐬𝐞𝐥-𝐎𝐜𝐜𝐥𝐮𝐬𝐢𝐨𝐧 𝐒𝐭𝐫𝐨𝐤𝐞𝐬 (𝐎𝐑𝐈𝐄𝐍𝐓𝐀𝐋-𝐌𝐞𝐕𝐎)
Among patients with stroke due to medium-vessel occlusion, thrombectomy led to functional independence at 90 days (in 58.6% of patients, vs. 46.6% with medical management) but also to a higher risk of intracranial hemorrhage.

𝐄𝐧𝐬𝐢𝐭𝐫𝐞𝐥𝐯𝐢𝐫 𝐟𝐨𝐫 𝐂𝐨𝐯𝐢𝐝-𝟏𝟗 𝐏𝐨𝐬𝐭𝐞𝐱𝐩𝐨𝐬𝐮𝐫𝐞 𝐏𝐫𝐨𝐩𝐡𝐲𝐥𝐚𝐱𝐢𝐬 𝐢𝐧 𝐇𝐨𝐮𝐬𝐞𝐡𝐨𝐥𝐝 𝐂𝐨𝐧𝐭𝐚𝐜𝐭𝐬 (𝐒𝐂𝐎𝐑𝐏𝐈𝐎-𝐏𝐄𝐏)
In the phase 3 SCORPIO-PEP trial, the 3C-like protease inhibitor ensitrelvir was more effective than placebo in preventing Covid-19 in household contacts of patients with SARS-CoV-2 infection.

𝐓𝐞𝐥𝐢𝐭𝐚𝐜𝐢𝐜𝐞𝐩𝐭 𝐟𝐨𝐫 𝐈𝐠𝐀 𝐍𝐞𝐩𝐡𝐫𝐨𝐩𝐚𝐭𝐡𝐲 — 𝐈𝐧𝐭𝐞𝐫𝐢𝐦 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐚 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐓𝐫𝐢𝐚𝐥 (𝐓𝐄𝐋𝐈𝐆𝐀𝐍)
An interim analysis of a phase 3 trial involving patients with IgA nephropathy showed that 39 weeks of treatment with telitacicept led to a greater reduction in the 24-hour urinary protein-to-creatinine ratio than placebo.

Read the full articles and Research Summaries at NEJM.org (link in bio).

04/06/2026

Research Summaries accompanying Original Articles in the May 7, 2026, issue of NEJM:

𝐋𝐞𝐟𝐭 𝐕𝐞𝐧𝐭𝐫𝐢𝐜𝐮𝐥𝐚𝐫 𝐔𝐧𝐥𝐨𝐚𝐝𝐢𝐧𝐠 𝐢𝐧 𝐇𝐢𝐠𝐡-𝐑𝐢𝐬𝐤 𝐏𝐞𝐫𝐜𝐮𝐭𝐚𝐧𝐞𝐨𝐮𝐬 𝐂𝐨𝐫𝐨𝐧𝐚𝐫𝐲 𝐈𝐧𝐭𝐞𝐫𝐯𝐞𝐧𝐭𝐢𝐨𝐧 (𝐂𝐇𝐈𝐏-𝐁𝐂𝐈𝐒𝟑)
Among patients undergoing complex PCI, elective unloading with a microaxial flow pump did not reduce the risk of major adverse clinical outcomes as compared with standard care.

𝐄𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐚𝐧𝐝 𝐒𝐚𝐟𝐞𝐭𝐲 𝐨𝐟 𝐚𝐧 𝐦𝐑𝐍𝐀 𝐒𝐞𝐚𝐬𝐨𝐧𝐚𝐥 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐳𝐚 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐢𝐧 𝐀𝐝𝐮𝐥𝐭𝐬 (𝐅𝐥𝐮𝐞𝐧𝐭)
Among adults 50 years of age or older, fewer cases of confirmed influenza-like illness were observed with an mRNA influenza vaccine than with standard vaccines. Reactogenicity was higher with the mRNA vaccine.

𝐎𝐫𝐚𝐥 𝐈𝐯𝐞𝐫𝐦𝐞𝐜𝐭𝐢𝐧 𝐚𝐧𝐝 𝟓% 𝐏𝐞𝐫𝐦𝐞𝐭𝐡𝐫𝐢𝐧 𝐂𝐫𝐞𝐚𝐦 𝐭𝐨 𝐓𝐫𝐞𝐚𝐭 𝐒𝐞𝐯𝐞𝐫𝐞 𝐒𝐜𝐚𝐛𝐢𝐞𝐬 (𝐆𝐀𝐋𝐄 𝐂𝐑𝐔𝐒𝐓𝐄𝐃)
In the GALE CRUSTED trial, higher-dose ivermectin plus permethrin was no better than standard-dose ivermectin plus permethrin, but both regimens were effective, leading to cure in 75% and 82% of the patients, respectively.

Read the full articles and Research Summaries at NEJM.org (link in bio).

01/05/2026

THE IMPORTANCE OF STUPIDITY IN SCIENTIFIC RESEARCH

A must-read for PhD students! This piece shares powerful tips on not just handling, but truly learning to embrace the feeling of living in the unknown. Really it's a well know feeling that's impossible to avoid whrn you love resesrch. You can't have a right answer to common scientific topics. Because you must found your answers and not repeat those already known from other people. That's " YOU KNOW , YOU DONT KNOW " not strange or stupid conclusion, but the clever we can heve as thinking people.

23/04/2026

New in the April 23, 2026, issue of NEJM: ⁣
⁣
Antihypertensive Pill after Intracerebral Hemorrhage (TRIDENT trial) ⁣
⁣
Oral Nirmatrelvir–Ritonavir for Covid-19 (PANORAMIC and CanTreatCOVID trials)⁣
⁣
tE2 Patches in Locally Advanced Prostate Cancer (STAMPEDE-1 and PATCH trials) ⁣
⁣
Ketamine or Etomidate for Tracheal Intubation (RSI trial) ⁣
⁣
Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣
⁣

23/04/2026

Research Summaries accompanying Original Articles in the March 26, 2026, issue of NEJM: ⁣
⁣
𝐀𝐭𝐞𝐳𝐨𝐥𝐢𝐳𝐮𝐦𝐚𝐛 𝐩𝐥𝐮𝐬 𝐅𝐎𝐋𝐅𝐎𝐗 𝐟𝐨𝐫 𝐒𝐭𝐚𝐠𝐞 𝐈𝐈𝐈 𝐝𝐌𝐌𝐑 𝐂𝐨𝐥𝐨𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 (𝐀𝐓𝐎𝐌𝐈𝐂) ⁣
In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue. ⁣
⁣
𝐄𝐚𝐫𝐥𝐲 𝐒𝐮𝐫𝐠𝐞𝐫𝐲 𝐨𝐫 𝐂𝐨𝐧𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐯𝐞 𝐂𝐚𝐫𝐞 𝐟𝐨𝐫 𝐀𝐬𝐲𝐦𝐩𝐭𝐨𝐦𝐚𝐭𝐢𝐜 𝐀𝐨𝐫𝐭𝐢𝐜 𝐒𝐭𝐞𝐧𝐨𝐬𝐢𝐬 (𝐑𝐄𝐂𝐎𝐕𝐄𝐑𝐘) ⁣
Early surgery in asymptomatic patients with very severe aortic stenosis led to a lower risk of a composite of operative mortality or death from cardiovascular causes at 10 years than conservative care. ⁣
⁣
𝐃𝐞𝐧𝐠𝐮𝐞 𝐕𝐢𝐫𝐮𝐬 𝐒𝐮𝐩𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐛𝐲 𝐖𝐨𝐥𝐛𝐚𝐜𝐡𝐢𝐚-𝐈𝐧𝐟𝐞𝐜𝐭𝐞𝐝 𝐌𝐨𝐬𝐪𝐮𝐢𝐭𝐨𝐞𝐬 ⁣
In a report from Singapore, the release of wolbachia-infected, irradiated male 𝘈𝘦𝘥𝘦𝘴 𝘢𝘦𝘨𝘺𝘱𝘵𝘪 mosquitoes resulted in a reduction in the vector population and in the risk of dengue infection. ⁣
⁣
Read the full articles and Research Summaries at NEJM.org (link in bio). ⁣
⁣

23/04/2026

New in the April 16, 2026, issue of NEJM: ⁣
⁣
Asundexian for Secondary Stroke Prevention (phase 3 OCEANIC-STROKE trial) ⁣
⁣
Adjunctive Prednisolone for Kawasaki Disease (phase 3 trial) ⁣
⁣
Selective Decontamination of the Digestive Tract (SuDDICU trial) ⁣
⁣
Ianalumab plus Eltrombopag in Immune Thrombocytopenia (phase 3 VAYHIT2 trial) ⁣
⁣
Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣
⁣

23/04/2026

Research Summaries accompanying Original Articles in the April 16, 2026, issue of NEJM: ⁣
⁣
𝐀𝐬𝐮𝐧𝐝𝐞𝐱𝐢𝐚𝐧 𝐟𝐨𝐫 𝐒𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲 𝐒𝐭𝐫𝐨𝐤𝐞 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 (𝐎𝐂𝐄𝐀𝐍𝐈𝐂-𝐒𝐓𝐑𝐎𝐊𝐄) ⁣
In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. ⁣
⁣
𝐑𝐚𝐧𝐝𝐨𝐦𝐢𝐳𝐞𝐝 𝐓𝐫𝐢𝐚𝐥 𝐨𝐟 𝐀𝐝𝐣𝐮𝐧𝐜𝐭𝐢𝐯𝐞 𝐏𝐫𝐞𝐝𝐧𝐢𝐬𝐨𝐥𝐨𝐧𝐞 𝐟𝐨𝐫 𝐊𝐚𝐰𝐚𝐬𝐚𝐤𝐢 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 ⁣
In a phase 3, randomized trial involving 3208 children with Kawasaki disease, adding prednisolone to standard primary therapy did not reduce the incidence of coronary-artery lesions at 1 month. ⁣
⁣
𝐃𝐞𝐜𝐨𝐧𝐭𝐚𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐃𝐢𝐠𝐞𝐬𝐭𝐢𝐯𝐞 𝐓𝐫𝐚𝐜𝐭 𝐝𝐮𝐫𝐢𝐧𝐠 𝐕𝐞𝐧𝐭𝐢𝐥𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐂𝐔 (𝐒𝐮𝐃𝐃𝐈𝐂𝐔) ⁣
In the SuDDICU trial of patients undergoing mechanical ventilation in the intensive care unit, selective decontamination of the digestive tract did not result in a lower incidence of in-hospital death than standard care alone. ⁣
⁣
𝐈𝐚𝐧𝐚𝐥𝐮𝐦𝐚𝐛 𝐩𝐥𝐮𝐬 𝐄𝐥𝐭𝐫𝐨𝐦𝐛𝐨𝐩𝐚𝐠 𝐢𝐧 𝐈𝐦𝐦𝐮𝐧𝐞 𝐓𝐡𝐫𝐨𝐦𝐛𝐨𝐜𝐲𝐭𝐨𝐩𝐞𝐧𝐢𝐚 (𝐕𝐀𝐘𝐇𝐈𝐓𝟐) ⁣
In the VAYHIT2 phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. ⁣
⁣
Read the full articles and Research Summaries at NEJM.org (link in bio). ⁣
⁣